UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

The impact of intra‐clonal heterogeneity on the treatment of multiple myeloma

British journal of haematology, 2014-05, Vol.165 (4), p.441-454

2014

Link zum Volltext

Verfügbarkeit prüfen

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

Leukemia, 2019-11, Vol.33 (11), p.2628-2639

2019

Link zum Volltext

Verfügbarkeit prüfen

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

Clinical cancer research, 2015-10, Vol.21 (19), p.4384-4390

2015

Link zum Volltext

Verfügbarkeit prüfen

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma

Blood, 2013-07, Vol.122 (2), p.219-226

2013

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma

Translational research : the journal of laboratory and clinical medicine, 2015-06, Vol.165 (6), p.641-650

2015

Link zum Volltext

Verfügbarkeit prüfen

Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients

Bone marrow transplantation (Basingstoke), 2021-05, Vol.56 (5), p.1209-1212

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling

Frontiers in immunology, 2023-03, Vol.14, p.982720-982720

2023

Link zum Volltext

Verfügbarkeit prüfen

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)

Journal of cancer research and clinical oncology, 2020-03, Vol.146 (3), p.749-759

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

Leukemia, 2020-07, Vol.34 (7), p.1972-1972

2020

Link zum Volltext

Verfügbarkeit prüfen

A digital twin model for evidence-based clinical decision support in multiple myeloma treatment

Frontiers in digital health, 2023-12, Vol.5, p.1324453-1324453

2023

Link zum Volltext

Verfügbarkeit prüfen

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT

HemaSphere, 2023-08, Vol.7 (S3), p.e2621605-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5001-5007

2009

Link zum Volltext

Verfügbarkeit prüfen

First line vs delayed transplantation in myeloma: Certainties and controversies

World journal of transplantation, 2016-06, Vol.6 (2), p.321-330

Brioli, Annamaria

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Blood, 2011-12, Vol.118 (23), p.5989-5995

2011

Link zum Volltext

Verfügbarkeit prüfen

Differences due to socio-economic status, genetic background and sex in cancer and precision medicine - An intersectional approach to close the care gap for marginalized groups

Deutsche medizinische Wochenschrift (1946), 2023-04, Vol.148 (9), p.528

2023

Link zum Volltext

Verfügbarkeit prüfen

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Leukemia, 2014-02, Vol.28 (2), p.384-390

2014

Link zum Volltext

Verfügbarkeit prüfen

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3911-3920

2015

Link zum Volltext

Verfügbarkeit prüfen

Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia

British journal of haematology, 2022-07, Vol.198 (2), p.338-348

2022

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide combinations are a safe and effective option after daratumumab failure

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (9), p.6569-6574

2023

Link zum Volltext

Verfügbarkeit prüfen

Melphalan 200 mg/m.sup.2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients

Bone marrow transplantation (Basingstoke), 2021-05, Vol.56 (5), p.1209

2021

Link zum Volltext

Verfügbarkeit prüfen

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

Annals of hematology, 2019-03, Vol.98 (3), p.713-722

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(111)

Publikationsform

Sprache

Englisch
(120)
Japanisch
(7)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(44)
Hematology
(36)
Oncology
(27)
Multiple Myeloma
(24)
Female
(22)
Male
(22)
Middle Aged
(21)
Multiple Myeloma - Drug Therapy
(21)
Aged
(19)
Adult
(15)
Multiple Myeloma - Therapy
(12)
Treatment Outcome
(12)
Multiple Myeloma - Genetics
(11)
Multiple Myeloma - Mortality
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Aged, 80 And Over
(9)
Bortezomib
(9)
Multiple Myeloma - Diagnosis
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The impact of intra‐clonal heterogeneity on the treatment of multiple myeloma

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma

Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma

Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients

Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling

Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN)

Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

A digital twin model for evidence-based clinical decision support in multiple myeloma treatment

P960: EXTRAMEDULLARY MYELOMA REMAINS AN UNMET CLINICAL NEED EVEN IN THE ERA OF NOVEL AGENT. ANALYSIS OF THE SINGLE CENTER MCOHORT

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma

First line vs delayed transplantation in myeloma: Certainties and controversies

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Differences due to socio-economic status, genetic background and sex in cancer and precision medicine - An intersectional approach to close the care gap for marginalized groups

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia

Pomalidomide combinations are a safe and effective option after daratumumab failure

Melphalan 200 mg/m.sup.2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma

Suchergebnisse filtern